NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
NatureWise Biotech & Medicals Corporation (4732) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.009x
Based on the latest financial reports, NatureWise Biotech & Medicals Corporation (4732) has a cash flow conversion efficiency ratio of -0.009x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-6.52 Million) by net assets (NT$718.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NatureWise Biotech & Medicals Corporation - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how NatureWise Biotech & Medicals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NatureWise Biotech & Medicals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NatureWise Biotech & Medicals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Hydrogen Corp
PINK:FHYDF
|
0.039x |
|
CyberCatch Holdings Inc.
V:CYBE
|
2.671x |
|
WIN HANVERKY
MU:N2R
|
0.035x |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
N/A |
|
Alfabs Australia Ltd
AU:AAL
|
0.143x |
|
Alpha Exploration Ltd
V:ALEX
|
-0.010x |
|
Soosung Innovation Co. Ltd.
KQ:084180
|
0.042x |
|
BCWORLD PHARM. Co. Ltd
KQ:200780
|
0.020x |
Annual Cash Flow Conversion Efficiency for NatureWise Biotech & Medicals Corporation (2016–2024)
The table below shows the annual cash flow conversion efficiency of NatureWise Biotech & Medicals Corporation from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$783.56 Million | NT$-2.79 Million | -0.004x | -103.63% |
| 2023-12-31 | NT$633.56 Million | NT$62.20 Million | 0.098x | +354.65% |
| 2022-12-31 | NT$641.51 Million | NT$13.85 Million | 0.022x | -60.02% |
| 2021-12-31 | NT$624.35 Million | NT$33.72 Million | 0.054x | -41.85% |
| 2020-12-31 | NT$598.31 Million | NT$55.57 Million | 0.093x | +20.79% |
| 2019-12-31 | NT$532.74 Million | NT$40.96 Million | 0.077x | +198.60% |
| 2018-12-31 | NT$264.11 Million | NT$-20.60 Million | -0.078x | +59.58% |
| 2017-12-31 | NT$279.00 Million | NT$-53.83 Million | -0.193x | -8.14% |
| 2016-12-31 | NT$339.50 Million | NT$-60.57 Million | -0.178x | -- |